Abstract Pro-inflammatory cytokines induce meniscal matrix degradation and inhibition of endogenous repair mechanisms, but the pathogenic mechanisms behind this are mostly unknown. Therefore, we investigated details of interleukin-1 (IL-1α)-induced aggrecan turnover in mature meniscal tissue explants. Fibro-cartilagenous disks (3 mm diameter×1 mm thickness) were isolated from the central, weight-bearing region of menisci from 2-year-old cattle. After 3 or 6 days of IL-1α-treatment, GAG loss (DMMB assay), biosynthetic activity ([ 35 SO 4 ]-sulfate and [ 3 H]-proline incorporation), gene expression (quantitative RT-PCR) and the abundance (zymography, Western blot) of matrix-degrading enzymes and specific aggrecan products were determined. Meniscal fibrocartilage had a 4-fold lower GAG content (per wet weight) than adjacent articular cartilage, and expressed MMPs-1, -2, -3 and ADAMTS4 constitutively, whereas ADAMTS5 m-RNA was essentially undetectable. Significant IL-1 effects were a decrease in biosynthetic activity, an increase in GAG release and in the expression/abundance of MMP-2, MMP-3 and ADAMTS4. Fresh tissue contained aggrecan core protein products similar to those previously described for bovine articular cartilage of this age. IL-1 induced the release of aggrecanase-generated CS-substituted products including both high (>250 kDa) and low molecular weight (about 75 kDa) species. TIMP-3 (but not TIMP-1 and -2 or a broad spectrum MMP inhibitor) inhibited IL-1-dependent GAG loss. In addition, IL-1 induced the release of preformed pools of three known G1-bearing products. We conclude that aggrecanases are responsible for IL-1-stimulated GAG release from meniscal explants, and that IL-1 also stimulates release of G1-bearing products, by a process possibly involving hyaluronan fragmentation.
Introduction
Pathological changes of the knee meniscus, following from direct injury or acute joint inflammation, have been shown to contribute to the initiation and progression of knee joint diseases like osteoarthritis (OA) (Rupp et al. 2002; Carlson et al. 2002) . It is therefore important to understand the cellular mechanisms responsible for meniscal degradation and cellular or matrix changes which might prevent intrinsic or therapeutic meniscal repair.
Increased levels of pro-inflammatory cytokines, such as IL-1, have been found in the synovial fluid of OA or rheumatoid arthritic joints (Schlaak et al. 1996) , and it has recently been shown that IL-1 is able to inhibit the intrinsic meniscal repair response after injury in explants (Hennerbichler et al. 2007; Wilusz et al. 2008) . We therefore set out to determine whether the established role of ADAMTS-aggrecanases in articular degradation in explants and in vivo also applies to IL-1-induced depletion of meniscal aggrecan.
Members of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family are known to be responsible for much, if not all, of the destructive (GAG releasing) aggrecanolysis which occurs in both OA and RA joints (Sandy et al. 1992; Lohmander et al. 1993) . Both ADAMTS4 and ADAMTS5 can generate the G1-NITEGE392 and 393ARGS-G2-ELE1499/EEE1685 products from aggrecan which are found in articular cartilage, meniscal cartilage and soft tissues within the joint space. This proteolysis is very damaging for tissue function, since it results in total loss of the GAG-binding domains of aggrecan and accumulation of G1-NITEGE392 in the tissue. Recently, an accumulated m-calpain-generated aggrecan "doubleglobe" product (G1-G2-GVA719) has been identified in both bovine and human articular cartilages where it appears to be present in amounts similar to G1-NITEGE (Oshita et al, 2004; Maehara et al. 2007 ). Published studies (Shin et al. 2003; Wilson et al. (2009) have described the GAG-releasing effect of IL-1 on explanted meniscal tissue (mixed cartilagenous and fibrous) from pigs and immature cattle, respectively. A potent broad-spectrum metalloproteinase inhibitor protected bovine explants from IL-1-induced loss of both GAG and compressive properties. However in this study with immature meniscus, the nature of the GAG-bearing aggrecan fragments released during IL-1 treatment was not evaluated and the identity of the proteinases responsible was not fully established. We therefore decided to investigate the mature bovine meniscus in explant cultures with a focus on the identification of the proteinases involved in aggrecan turnover in vivo (by analysis of products in fresh tissue) and during IL-1 treatment ex vivo. Our data show that both aggrecanase and calpain activities cleave meniscal aggrecan in vivo, whereas IL-1-induced GAG loss from explants is due to aggrecanase (but probably not m-calpain) activity.
Materials and methods

Isolation and culturing of meniscal and articular cartilage explant disks
Meniscal explant disks were isolated from 16-to 24-month-old bovine menisci. Tissue cylinders (10 mm in diameter) were punched perpendicular to the meniscus bottom surface (Fig. 1a) . One millimetre of the bottom surface (normally adjacent to the tibial articular cartilage surface) was removed and about four smaller explant disks (3 mm in diameter×1 mm thick) were isolated from this using a biopsy punch (Unipunch, Lamoral), weighed and cultured in Dulbecco`s Modified Eagle's medium (DMEM supplemented with 100 U/ml penicillin G, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B; Sigma) in a 37°C, 5% CO 2 environment. Three explant disks per well of a 24-well plate were cultured for either 3 days (for histology, gene expression, isotope incorporation and Western analysis) or 6 days (for IL-1 doseresponse, medium change after 3 days) in 1 ml medium with or without recombinant human IL-1α (R & D Systems). Treated and control discs were from the same anatomical location. MMP-inhibitor used was CGS (27023A; Calbiochem, Germany). In experiments with TIMPs (R & D Systems) only one meniscal explant/well was cultured in 200 µl medium in 96-well plates. For articular cartilage studies, cartilage/bone cylinders (1 cm in diameter) were drilled out of the femoropatellar groove, and 1-mm-thick sections of cartilage were cut parallel to the surface. Then, 3-mm disks were punched out of these sections and cultured under the conditions used for meniscal explants.
Histology and immunohistochemistry
Explants were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and serial sections (7 µm) were cut sagittally through the entire width of the explant disks. Sections were immobilized on glass slides, deparaffinized and stained either with toluidine blue or for immunoreactivity of anti-NITEGE392 (Affinity Bioreagents/Thermo Fisher). For immunostaining, sections were heated for 2.5 min in a digester (in 0.01 M citric acid, pH 6.0, 100°C), incubated overnight at 4°C with anti-NITEGE (17 ug/ml) in 1% BSA, PA1-1746; Affinity BioReagents, Golden, USA), rinsed in TRISNaCl, incubated with the AlexaFluor 488 goat antirabbit IgG (1:500) for 1 h at room temperature, rinsed again and briefly incubated with bisbenzimide (Sigma), mounted with fluorescence mounting medium (Dako), and visualised using an Apotome (ZEISS) fluorescence microscope.
Measurement of glycosaminoglycan (GAG) and protein biosynthetic activity GAG content of papain-digested explants (see below) or media samples was determined by DMMB dye assay (Loening et al. 2000) In the collagen bundles lie small fibroblastic-like cells (black arrowheads), whereas in the fibrocartilaginous tissue, which is around the collagen bundles (small black arrows) the cells are round (white arrows) and surrounded by purple staining, indicating negative charges in the matrix; bar 50 µm. e Influence of interleukin-1 (IL-1) on cumulative GAG release into the culture medium during 6 days of incubation of bovine meniscal explants (n=6, *P<0.05, ww wet weight). Values are shown as mean+SEM Pharmacia) and 10% FBS for 6-8 h at 37°C under freeswelling conditions immediately after IL-1α treatment, washed in PBS containing 0.5 mM proline (to remove unincorporated isotope) and digested overnight in 1 ml of papain solution [0.125 mg/ml (2.125 U/ml; Sigma), 0.1 M Na 2 HPO 4 , 0.01 M Na-EDTA, 0.01 ML-cysteine, pH 6.5] at 65°C for counting. Data is expressed as cpm/mg wet weight and normalized to incorporation into untreated control tissue, which was set to 100%.
Measurement of peak stresses
Biomechanical testing of the tissue was performed after IL-1-treatment using a computer-controlled loading device described elsewhere (Kurz et al. 2001) . A single uniaxial unconfined compression with 10% strain was applied with a velocity of 0.1 mm/s to groups of three meniscal explants and peak stresses were recorded (in MPa) during compression.
Real time RT-PCR
Quantitative reverse transcriptase-polymerase reaction (real time RT-PCR) was performed using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as reference gene to determine gene expression levels. Meniscal explants (approximately 13=100 mg wet weight from each group) were flash frozen after 3 days of culture, pulverized, and total RNA was extracted using the TRIZOL reagent (1 ml/100 mg wet weight tissue; Invitrogen, Carlsbad, CA, USA). RNA was quantified (OD 260 /OD 280 nm) and digested with DNase (65°C for 10 min; Promega). Real time RT-PCR was done with the Qiagen QuantiTect SYBR ® Green RT-PCR Kit (Qiagen) according to the manufacturer´s instructions. Bovine primers (0.5 µM) were: GAPDH (S: 5′-ATC AAG AAG GTG GTG AAG CAG G-3′; AS: 5′-TGA GTG TCG CTG TTG AAG TCG-3′; product size 101 bp); MMP-1 (S: 5′-GGA CTG TCC GGA ATG AGG ATC T-3′; AS: 5′-TTG GAA TGC TCA AGG CCC A-3′; product size 91 bp); MMP-2 (S: 5′-GTA CGG GAA TGC TGA CGG GGA ATA-3′; AS: 5′-CCA TCG CTG CGG CCT GTG TCT GT-3′; product size 93 bp); MMP-3 (S: 5′-CAC TCA ACC GAA CGT GAA GCT-3′; AS: 5′-CGT ACA GGA ACT GAA TGC CGT-3′; product size 109 bp); ADAMTS4 (S: 5′-GCT GCC CTC ACA CTG CGG AAC-3′; AS: 5′-TTG CCG GGG AAG GTC ACG-3′; product size 101 bp); ADAMTS5 (S: 5′-AAG CTG CCG GCC GTG GAA GGA A-3′; AS: 5′-TGG GTT ATT GCA GTG GCG GTA GG-3′; product size 196 bp). Conditions were: reverse transcription 30 min, 50°C; PCR initial activation step 15 min, 95°C; denaturation 15 s, 94°C; annealing 30 s, 60°C; extension 30 s, 72°C; optional: data acquisition 30 s, melting temperature 70-78°C. Data were calculated using the ΔΔC T -method.
Zymography
MMPs were assayed in 3-day conditioned media by standard gelatine and casein zymography (Manicourt et al. 1993 ) and identified by molecular weights and substrate specificity. Some samples were incubated with 1 mM APMA (4-aminophenylmercuric acetate) for 3 h at 37°C to activate matrix metalloproteinase-pro-forms before loading.
Western blot analyses of aggrecan products
For isolation of aggrecan products finely sliced meniscal explants were extracted for 48 h at 4°C in 4 M guanidine hydrochloride (10 mM MES, 50 mM sodium acetate, 5 mM EDTA, 0.1 mM AEBSF, 5 mM iodoacetic acid, 0.3 M aminohexanoic acid, 15 mM benzamidine, 1 µg/ml pepstatin, pH 6.8). Extracts were centrifuged and clear supernatants were dialysed against water for 24 h at 4°C. Conditioned culture mediums were supplemented with 5 mM EDTA and 0.1 mM AEBSF and dialyzed against water as above. Dialyzed samples were adjusted to 75% ethanol and precipitates were isolated by centrifugation, dried, dissolved in 50 mM sodium acetate, 50 mM TRIS, 10 mM EDTA, pH 7.6 and incubated for 1-2 h at 37°C with protease-free chondroitinase ABC. Deglycosylated samples were analyzed separately for aggrecan fragments with anti-G1 (described in Sandy et al. 2000) and anti-EEE1685/ELE1499 antibodies (described in Sandy and Verscharen 2001) . The SK-28 antibody, which specifically recognizes the neo-epitope GVA719, was a very kind gift from Dr. Shimizu, Department of Orthopaedic Surgery, Gifu University Graduate School of Medicine.
Western blot analysis of ADAMTS4
Approximately 100 mg tissue from each group (12-15 explants) were flash frozen after 3 days of culture, pulverized, and proteins were extracted for 20 h at 4°C using lysis buffer containing 50 mM TRIS-HCl (pH 7.0),100 mM NaCl, 0.5% Igepal (I3021; Sigma-Aldrich), and complete enzyme inhibitor mix (11836170001; Roche Deutschland Holding, Grenzach-Wyhlen, Germany). Protein concentration was determined in the supernatant by Bradford method (Bio-Rad, Hercules, CA), and 10 µg protein/lane was loaded. Gels were 12.5% polyacrylamide gel with 4% starter gel (Rotiphorese gel 30, 37.5:1, No. 3029.1; Roth, Karlsruhe, Germany), and PVDF membranes were Hybond-P (RPN 303 F; Amersham Biosciences/GE Healthcare, Munich, Germany). Membranes were incubated overnight with anti-ADAMTS4 polyclonal antibody (PA1-1750; Affinity Bioreagents, Rockford, IL, USA) at a concentration of 1 µg/ml at 4°C. They were washed and incubated with peroxidase-labeled goat anti-rabbit immu-noglobulin G (#31460; Pierce, Rockford, IL, USA) for 1 h at room temperature. Bands were visualized with the ECL Plus Western Blotting Detection System (RPN 2132; GE Healthcare, Munich, Germany). Membranes were stripped and restained using the polyclonal anti-GAPDH antibody (SC-25778, 0.8 µg/ml; Santa Cruz Biotechnology) to confirm equal protein loading in all lanes.
Statistics
Quantitative data are presented as mean±SEM (if not otherwise indicated), n represents the number of independent experiments. Statistical analysis of data was made using the two-tailed Student's t test. Differences were considered significant if P≤0.05.
Results
Histological characterization of meniscal explants
Meniscal explants were prepared from a defined anatomical location (Fig. 1a) . One flat side of the disks represented the original bottom surface of the meniscus (Fig. 1b) , resulting in a zonal structure of the disks: at the original surface a thin zone (about 30 µm) could be found with flat to oval cells (Fig. 1b and c) and fibres which appeared to be oriented in line with the surface. The rest of the tissue consisted of thick bundles of collagen fibres containing fibroblast-like cells (Fig. 1d) , and these bundles were embedded in fibrous cartilage with chondrocytic cells. Toluidine blue staining confirmed the presence of proteoglycans in both the fibrous and especially the fibrocartilagenous regions (Fig 1b-d) .
Effect of IL-1 on GAG release and content, stiffness and biosynthetic activity of meniscal explants
The GAG content of fresh meniscal explants was 14.2±0.9 µg/ mg wet weight (n=6). IL-1 treatment resulted in a significant concentration-dependent increase in the release of GAG over 6 days (Fig. 1e) which increased from about 3.5 ug/mg wet weight (control) to about 7.5 ug/mg wet weight. Accordingly, this was accompanied by a decrease in the tissue GAG content of 11.7±0.8 µg/mg (day 6, controls; n=6) to 7.7± 0.8 µg/mg (day 6, IL-1-treated; n=6). Since the total mean GAG content of the explant system (14.2 ug/mg wet weight) was essentially constant over 6 days in both controls and IL-1 cultures, it appears that there was no significant addition of CS-proteoglycan under either condition.
The IL-1-treatment markedly affected the compressive tissue properties. Peak stresses during a 10% uniaxial compression (strain rate 0.1 s −1 ) were about 0.8±0.2 MPa (n=3) in 3-day control tissue and about 0.4±0.1 MPa (n=3) after 3 days of IL-1 treatment. This difference in peak stress is consistent with the difference in GAG content of the tissue under these conditions (correlation coefficient r= −0.85, n=8). The biosynthetic activity of meniscal explants was also significantly inhibited by IL-1 treatment: Sulfate incorporation was reduced about 54% and proline incorporation about 26% compared to controls. IL-1 did not, however, alter the viability of the meniscal cells, since there were no significant changes relative to control in the ethidium bromide/FDA staining (<2% of the cells showed ethidium bromide staining in all experimental groups) or the numbers of apoptotic cells (apoptosis was evaluated by counting cells with nuclear blebbing in serial sections of the explants (controls: 1.9±0.3% cells with nuclear blebbing; IL-1: 2.6±0.6% cells; n=4).
In a parallel study with animal-matched articular cartilage explants, we found that the relative effects of IL-1 over control on both GAG release and biosynthetic activity were greater for articular cartilage than for meniscus. Basal GAG content in articular cartilage tissue (57.8 ± 4.9 µg/mg), was about 4-fold higher than in meniscal explants but only 10% (5.8 µg/mg±0.8; n=6) was released from control tissue during 6 days of culture. IL-1-treatment (10 ng/ml) increased GAG release about 2.8-fold (to 16.1 µg/mg±2.4, n=6). Sulfate and proline incorporations were decreased in articular cartilage by IL-1 treatment about 84% (n=6) and 76% (n=6) respectively, suggesting that articular chondrocytes are more sensitive than meniscal cells to IL-1-dependent inhibition of GAG and protein production.
Effect of IL-1 on MMP and ADAMTS mRNA levels MMP-1, -2, and-3 were found to be expressed constitutively and IL-1 had essentially no effect on MMP-1, but increased MMP-2 expression about 3-fold, and MMP-3 about 18-fold over controls (Fig. 2a) . The expression of ADAMTS4 was readily detected in controls, and there was a marked (but variable) up-regulation by IL-1 treatment (Fig. 2b) . The difference of ΔCT values in controls and IL-1-treated samples showed significant IL-1-dependent differences for MMP-3 and ADAMTS4 (mean difference in ΔCT values: 4.24±0.35 and 2.4±0.63, respectively; P< 0.05 in a paired two-tailed t test). In five separate experiments, ADAMTS5 mRNA was either undetectable (2 cases) or detected at very low levels and IL-1 did not seem to have a major effect on transcript abundance.
Effect of IL-1 on MMP and ADAMTS protein abundance
The IL-1-dependent induction of MMP-2 and MMP-3 gene expression apparently results in increased protein secretion for these proteinases since the only bands visible on zymography of IL-1 culture supernatants were identified as MMP-2 and -3 proteins on the basis of molecular size. Predominantly, the inactive pro-forms were detected ( Fig. 2c and d) . Pro-MMP-3 (∼57 kDa; according to Manicourt et al. 1993 ) was present at very low levels in control supernatants but markedly enhanced by IL-1, consistent with the RT-PCR data. As expected, APMA treatment before zymography converted pro-MMP-3 to the active form (45 kDa). The zymographic gelatinase activity of pro-MMP-2 (∼66 kDa) was constitutive and there was a slight IL-1-dependent increase of this activity, again consistent with the PCR data. On incubation with APMA before zymography, there was a partial conversion to active MMP-2 which migrated at 62 kDa.
Western blotting of conditioned medium for ADAMTS4 (Fig. 2e) showed the p75, p68, and p53 isoforms reported by Gao et al (2002) . Interestingly, IL-1 treatment enhanced the abundance of the highly active p53 form, consistent with a role for ADAMTS4 in meniscal aggrecanolysis. Similar changes in ADAMTS4 have been observed on IL-1 treatment of bovine articular cartilage (Patwari et al. 2005) .
Aggrecan processing in the meniscus
To delineate the nature of the proteinases involved in meniscal aggrecan processing, we next analyzed tissue extracts and conditioned medium by Western blot with antiaggrecan antibodies which detect aggrecan G1 domain or aggrecan neo-epitopes (see Fig. 3a ). It should be noted that we are proceeding here under the reasonable initial assumption that bovine aggrecan products, with the same electrophoretic and immunoreactivity properties, represent the same molecular species whether derived from articular Culture supernatants were assayed by casein (c) and gelatine (d) zymography for activity of MMPs after 3 days of incubation. The bands with proteolytic activity correspond presumably to pro-MMP-3 (∼55 kDa) and pro-MMP-2 (∼66 kDa), and are the only bands visible in the gel (Con control). APMA (4-aminophenylmercuric acetate) treatment before zymography converted pro-MMP-3 to the active form (45 kDa) and MMP-2 partially to the active form (62 kDa). e Western blot analysis of ADAMTS4 in medium showing an IL-1-dependent increase of the isoform p53 (Oshita et al. 2004 , Patwari et al. 2005 or meniscal cartilages.
Fresh meniscal tissue contained aggrecan core protein products (Fig. 3a , left lane) very similar to those previously described in detail for bovine articular cartilage of this age (Oshita et al. 2004 , Patwari et al. 2005 . IL-1 enhanced the abundance of both high (>250 kDa) and low molecular weight (about 75 kDa) aggrecanase-generated products in the medium which were detected with combined anti-ELE1499/anti-EEE1685 antibodies (see arrows, Fig. 3a , middle panel). Since anti-SELE (human sequence) does not readily detect the bovine product (GELE1499), it seems likely that both the immunoreactive reactive products terminate at the EEE1685 site. The migration behaviors suggest that the high molecular weight diffuse band is composed of both G1-G2-EEE1685 and 393ARGS-G2-EEE1685. The size of the 75-kDa product suggests that it has an N-terminus at about residue 1,350 (possibly due to a DLS1346/ 1347VLP cut by m-calpain; see Oshita et al. 2004 ) and a C-terminus at EEE1685. In addition, the IL-1 treatment caused a loss from the tissue (right-hand panels) of disperse G1-reactive products at about 120 kDa and 160 kDa, both of which react with SK-28 and can therefore be identified as the G1-G2-GVA719 species bearing the calpain-generated C-terminal neo-epitope (GVA). These released products were, as expected, detected by the anti-G1 antibody (see medium sample from IL-1 treated tissue; Fig. 3a ) in greater amounts in the IL-1 medium than control medium. In this regard, IL-1 also induced the release of the aggrecanase-generated product G1-NITEGE392; however, this does not necessarily imply (or exclude) that there is an increased cleavage of the TEGE392/393ARGS bond. This is because the fresh tissue contains abundant G1-NITEGE392 and IL-1 could bring about matrix changes (such as hyaluronan cleavage) which would be expected to enhance diffusional loss to the medium. Diffusional loss may be indeed an important pathway here, since the loss of G1-NITEGE392 from the tissue was accompanied by some appearance in the medium (Fig. 3a) . Another pathway to partly explain tissue loss here would be the possible IL-1- Fig. 3 Aggrecan fragments in meniscal tissue (T) or culture supernatants (M) after 3 days of incubation in the absence (C control) or presence of interleukin-1 (IL-1). a Aggrecan fragments were analyzed by Western blotting using anti-G1, SK-28, or combined anti-EEE1685/ELE1499 neoepitope antibodies. Arrows indicate changes in IL-1-treated samples. b,c Immunohistochemical detection of the distribution of aggrecan neoepitope NITEGE392 (green) in bovine meniscal tissue. Next to bisbenzimide staining of cellular nuclei (blue; arrowheads) there was little or no staining in the matrix of control explants but some cellular staining (b), while there was a strong staining of NITEGE392 in the matrix of fibrocartilaginous areas of explants incubated with IL-1 (c). Bars 50µm induced endocytosis of this product (Embry Flory et al. 2006 ) by meniscal cells.
In this regard, immunostaining of meniscal sections for the neoepitope NITEGE392 at 3 days showed this product to be barely detectable in control tissue (Fig. 3b) , but abundant in IL-1-treated tissue, particularly associated with cells/matrix apparently surrounding collagen fibrils in fibrocartilagenous areas (see Fig. 3c ). This increase with IL-1 appears to conflict with the western analysis of parallel samples, which showed a somewhat decreased signal with IL-1 (Fig. 3a) . This suggests that the two methods are at least partly detecting different pools of product, with the western blot evaluating the guanidine-extractable pool and the histology detecting only the pool with immunodetectable neo-epitope in fixed tissue sections.
Inhibitor studies also support a role for ADAMTS-aggrecanases
We also investigated whether the IL-1-induced GAG release was influenced by tissue inhibitors of metalloproteinases (TIMP-1, -2, and-3). TIMPs are known as potent inhibitors of MMPs, but TIMP-3 has the unique additional ability to inhibit the aggrecanases ADAMTS4 and-5 (Kashiwagi et al. 2001; Gendron et al. 2003) . Addition of TIMPs did not affect the GAG loss in control cultures (not shown), but the IL-1-induced GAG release was significantly reduced (about 65%) by TIMP-3 (0.1 µM) but not TIMP-1 and TIMP-2 at this concentration (Fig. 4a) . In fact, the inclusion of TIMP-1-or TIMP-2-enhanced IL-1 stimulated GAG release by about 40%, a finding which suggests that blocking MMPs (but not ADAMTSs) in this system actually promotes the catabolic effects of IL-1. Further work will be needed to determine the physiological relevance of this observation. These observations with TIMPs-1 and -2 were also supported by results with MMI270B (previously known as CGS27023A), a broad spectrum MMP inhibitor with nM IC 50 values against MMP3 (MacPherson et al., 1997) . MMI270B did not affect IL-1-induced meniscal GAG loss significantly (Fig. 4b) , until added at 26μM, consistent with there being no role for MMPs in this release process.
Discussion
Aggrecanase-mediated aggrecanolysis in the meniscus
We present data which clearly indicates that IL-1-mediated aggrecanolysis in explant cultures of mature menisci (which results in loss of matrix GAG and also loss of compressive properties) is due primarily to the action of one or more aggrecanases (as opposed to MMPs or m-calpain). We make this conclusion because the GAG loss is accompanied by the release of aggrecan products (not seen in controls) with the electrophoretic and/or immunoreactive properties of G1-G2-EEE1685, 393ARG-G2-EEE1685 and 1347VLP-EEE1685, all of which are CS-substituted aggrecanase-generated products. In addition, the highly effective aggrecanase inhibitor TIMP-3 (but not TIMP-1 or -2), blocked IL-1-induced GAG release. We have also presented data which would favor the involvement of ADAMTS4, rather than ADAMTS5, in causing GAG release in this system. This is because ADAMTS4 (but not ADAMTS5) gene expression is enhanced by IL-1 and the abundance of activated ADAMTS4 (p53) in the tissue is increased by IL-1. This situation is similar to that described by Patwari et al (2005) with articular explants; however, studies on the activation status of ADAMTS5 and experi- Fig. 4 Effects of TIMP-1, -2, and-3 (0.1 µM; a) or the MMP-inhibitor MMI270B (b) on IL-1-induced loss of glycosaminoglycans (GAG) after 3 days of incubation with or without interleukin-1 (IL-1). a White bar shows the IL-1-dependent GAG loss without TIMP treatment; mean values+SD, n=5; *P<0.001. b GAG content of meniscal explants after 6 days of treatment. Values are shown as means ± SEM (n=4); *P<0.05 ments with blocking antibodies to ADAMTS4 and ADAMTS5 will be needed to be more definitive on this question.
MMPs in the meniscus
We have also demonstrated that IL-1 treatment of the meniscus results in a marked release of pro-MMP-2 and especially pro-MMP-3 protein. However, the inability of TIMP-1, TIMP-2, and MMI270B to block GAG release from these explants makes it very unlikely that any MMPs are involved in the GAG release seen here. Moreover, MMPs most likely generate the G1-VDIPES360 product seen at 55 kDa (Fig. 3a, left panels) , and under IL-1 treatment this product was not changed in abundance or distribution between tissue and medium. In this regard, it continues to appear that the G1-NITEGE392 and G1-VDIPES360 products are present in different tissue pools, as discussed in a recent review of this area (Sandy 2006) . It should be noted that the increased secretion of MMPs from meniscal explants may partly explain the increased MMP levels which have been described in OA animal models and human OA articular cartilage, as well as in the synovial fluid of RA and OA patients (Lohmander et al. 1993; Bluteau et al. 2001 ).
m-Calpain-generated aggrecan products in meniscus and articular cartilage
The aggrecan products at about 120 kDa and 160 kDa, which were detected in tissue extracts with SK-28 (Fig. 3a , right panel), appear to represent the G1-G2-GVA719 isoforms generated by m-calpain cleavage of aggrecan and previously identified in extracts of fresh bovine cartilage (Oshita et al. 2004) . In the present paper, we have shown that a marked proportion (perhaps 50%) of these products are lost from IL-1-treated tissue relative to controls (Fig. 3a , right panels). However, since these products do not include the CS-rich or KS-rich regions of aggrecan, their loss does not contribute to the observed GAG loss. Nonetheless, their co-ordinated release suggests that one effect of IL-1 treatment in these explants is to enhance the mobilization and diffusional loss of endogenous G1-NITEGE392 and both forms of G1-G2-GVA719. This indicates that these products are present in the same metabolic pool and that loss to the medium might result from an induction of hyaluronidase activity and/or loss of binding interactions between hyaluronan and a cell surface receptor such as CD44 (Sugimoto et al. 2004; Knudson and Loeser 2002) . In this regard, immunostaining for m-calpain and G1-G2-GVA719 (data not shown) indicated that the proteinase and the product are concentrated within and/or around cells in the cartilagenous area of the mature meniscus.
In terms of a possible role for G1-NITEGE392 (and G1-G2-GVA719), it may be relevant that G1-NITEGE392 accumulates in the meniscus (and ligaments) of foetal and newborn bovines before it appears in age-matched epiphyseal cartilages (Sandy et al. 1995; Wilson et al. 2009) suggesting that it may be involved in the formation and growth of fibrous joint tissues. Finally, the results described here are somewhat at variance with the conclusions drawn from the work of Wilson et al. (2009) , although it must be noted that this earlier study was substantially different in that it was done with full-depth explants of mid-substance from immature bovine menisci, whereas the present study was confined to mature meniscal tissue taken immediately adjacent to the articular surface. Wilson et al. (2009) concluded, on the basis of the effects of low molecular weight inhibitors, that both MMPs and aggrecanases (other than ADAMTS4/5) are responsible for IL-1-induced GAG loss. In that study, however, apart from the major design differences, it cannot be excluded that the ADAMTS4/5 inhibitor (RO3310769) was ineffective due to issues of chemical instability or poor cell accessability, problems which did not appear to apply to TIMP-3 in the present work.
